50x faster screening with FIDA
How did Tozaro boost their screening throughputfrom 6 to up to 288 samples daily, reducing monthsof work to just days?
%20(1).webp)
Tozaro (Previously MIP Discovery / Diagnostics) ingeniously reimagined its affinity reagentscreening workflow using FIDA, transforming interaction analysis from slow and laborintensive to fast and precise. The benefit? They managed to achieve greater efficiency,scalability, and decision-making power in molecular interaction analysis.
Problems
Traditional techniques such as Surface Plasmon Resonance (SPR) createdthroughput bottlenecks, limiting the ability to evaluate large polymer libraries quickly andcost-effectively.
Solutions
FIDA-Driven Workflow:
Primary Screen →
Rapid elimination ofnon-binders using afluorescently labeledindicator. Throughput:up to 3× 96-wellplates/day (288samples).
ConfirmatoryScreen →
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique.
Kd Determination →
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique.
Reverse Titration →
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique.
After these steps, only selected candidates are progressed to SPR to assess surfaceimmobilization effects, eliminating the need for SPR in primary screening. By their innovativeadaptation of FIDA, Tozaro replaced SPR for most polymer interaction screening analyses,streamlining research and accelerating discovery.
The benefits?
By replacing SPR with FIDA for polymer interaction analysis, Tozaro streamlined research, reduced time-to-decision, and dramatically increased efficiency in polymer screening workflows.
SPR:
16+ days | ~6 polymers/day
FIDA:
30min - 3 hours | up to 288 polymers/day
Ask yourself, what could you do with such time and sample savings?
100% Plasma binding measurements
that change big pharma’s workflows
How did a large pharmaceutical company measure binding affinityand kinetics in-solution & in 100% plasma?
A big, German, pharma company had the ambition to measure Kd and binding kinetics in100% plasma to correlate it with values from surface based technologies in buffer solutions -& they succeeded by using the right technology to do so.
Problems
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse.
Solutions
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse.
1. section heading
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique.
2. section heading
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique.
3. section heading
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique.
4. section heading
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
.jpg)
What they discovered?
These differences highlighted why early validation of in-solution kinetics in plasma is critical to avoid investing in misleading buffer-based data. The in-solution Kd in plasma was 8×weaker than in buffer, revealing how plasma components affect affinity. On-rates were 5× slower, and off-rates were 2× faster in plasma than in buffer. The difference between buffer and plasma is clearly distinguishable with FIDA technology.
.jpg)
The benefits?
- The gain of physiologically relevant kinetic data early in the drug development process.
- By integrating early-stage FIDA measurementsin 100% plasma, they streamlined their workflow,improved candidate selection,and minimized late-stage failures.
- The insights allowed them to confidently prioritize viabledrug candidates, avoid costly setbacks, and makemore reliable, physiologically relevant decisions.
- Ultimately accelerating the drug development process while reducing costs.
Screening denovo designedprotein binders inunpurified lysate
.avif)
Problems
Computational design produces binders at scale, but screening themefficiently is the bottleneck. Traditional validation does not provide structural data, requirespurified material and multiple assays to determine whether a design binds with sufficientaffinity and stability, slowing down the transition from design to decision.
Solutions
By providing functional and structural data in a single measurement and directly from crude expression material, FIDA allows evaluation of binding, stability, and solution behaviour at an early stage. This shifts validation from a sequential, resource-intensive process to an early, decision-driven step.
How to screen de novo design protein binders in unpurified lysate using flow induced dispersion analysis?
Lear about streamline binder
Screening de novo designed protein bindersin unpurified lysate using flow induceddispersion analysis
.png)
If we sparked your curiosity, go ahead, book a discovery call to explore if FIDA could be something just right for you.